To include your compound in the COVID-19 Resource Center, submit it here.

Spark’s approach to the problem of redosing AAV gene therapies

Spark aims to solve one of the big problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa has been developing for transplant rejection.

Past infections with adenoviruses or adeno-associated viruses can lead to pre-existing antibodies against viral vectors that both pose a safety risk

Read the full 501 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE